The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives
Open accessAbstract
Nanomedicine research has increased drastically over the past ten years, however, before clinical translation many regulatory factors must be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals, antioxidants and functional foods: impact on human health
Lobo, V, Patil, A., Phatak, A., & Chandra, N. (2010) · Pharmacognosy Reviews · doi:10.4103/0973-7847.70902 · Cited by 5,435
Edmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2014.573 · Cited by 2,515
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990
Energy storage: The future enabled by nanomaterials
Pomerantseva, E., Bonaccorso, F., Feng, X., Cui, Y., & Gogotsi, Y. (2019) · Science · doi:10.1126/science.aan8285 · Cited by 1,927
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials
Singh, N., Manshian, B., Jenkins, G. J. S., Griffiths, S. M., Williams, P. M., Maffeis, T. G. G., Wright, C. J., & Doak, S. H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.04.009 · Cited by 1,184
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Shape-Controlled Synthesis and Surface Plasmonic Properties of Metallic Nanostructures
Xia, Y., & Halas, N. J. (2005) · MRS Bulletin · doi:10.1557/mrs2005.96 · Cited by 925
Nanomedicine: Principles, Properties, and Regulatory Issues
Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00360 · Cited by 790
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
Nanomedicine scale-up technologies: feasibilities and challenges
Paliwal, R., Babu, R. J., & Palakurthi, S. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0177-9 · Cited by 466
Regulatory aspects on nanomedicines
Sainz, V., Conniot, J., Matos, A. I., Peres, C., Zupanǒiǒ, E., Moura, L., Silva, L. C., Florindo, H. F., & Gaspar, R. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.023 · Cited by 417
Cloaking nanoparticles with protein corona shield for targeted drug delivery.
Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., et al. (2018) · Nature communications · doi:10.1038/s41467-018-06979-4 · Cited by 409
Current status and future prospects of nanotechnology in cosmetics
Mihranyan, A., Ferraz, N., & Strømme, M. (2012) · Progress in Materials Science · doi:10.1016/j.pmatsci.2011.10.001 · Cited by 268
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
Meunier, F., Prentice, H. G., & Ringden, O. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.83 · Cited by 247
On the issue of transparency and reproducibility in nanomedicine
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufés, C., Owen, A., Rannard, S., Scott, C., Chen, C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0496-9 · Cited by 242
Self-citationInfluence of Nanoparticles on Blood–Brain Barrier Permeability and Brain Edema Formation in Rats
Sharma, H. S., Hussain, S., Schlager, J., Ali, S. F., & Sharma, A. (2010) · Acta Neurochirurgica Supplementum · doi:10.1007/978-3-211-98811-4_65 · Cited by 209
Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?
Mühlebach, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.024 · Cited by 203
Kermanizadeh, A., Balharry, D., Wallin, H., Loft, S., & Møller, P. (2015) · Critical Reviews in Toxicology · doi:10.3109/10408444.2015.1058747 · Cited by 183
From Nanotechnology to Nanomedicine: Applications to Cancer Research
Seigneuric, R., Markey, L., S.A. Nuyten, D., Dubernet, C., T.A. Evelo, C., Finot, E., & Garrido, C. (2010) · Current Molecular Medicine · doi:10.2174/156652410792630634 · Cited by 182
Regulating Nanomedicine – Can the FDA Handle It?
Bawa, R. (2011) · Current Drug Delivery · doi:10.2174/156720111795256156 · Cited by 160
Regulating Nanomedicine at the Food and Drug Administration
Paradise, J. K. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.347 · Cited by 152
Agrahari, V., & Hiremath, P. S. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0039 · Cited by 142
The solid progress of nanomedicine
Martins, J. P., das Neves, J., de la Fuente, M., Celia, C., Florindo, H. F., Günday-Türeli, N., Popat, A., Santos, J. L., Sousa, F., Schmid, R., et al. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00743-2 · Cited by 131
Challenges Posed by The Scale-Up of Nanomedicines
Muthu, M. S., & Wilson, B. (2012) · Nanomedicine · doi:10.2217/nnm.12.3 · Cited by 124
Nanomedicines: The magic bullets reaching their target?
Flühmann, B., Ntai, I., Borchard, G., Simoens, S., & Mühlebach, S. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.11.019 · Cited by 116
Nanomedicines in the EU—Regulatory Overview
Pita, R., Ehmann, F., & Papaluca, M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9967-1 · Cited by 101
Hoskins, C., Wang, L., Cheng, W. P., & Cuschieri, A. (2012) · Nanoscale Research Letters · doi:10.1186/1556-276x-7-77 · Cited by 88
Self-citationTransforming Nanomedicines From Lab Scale Production to Novel Clinical Modality
Landesman‐Milo, D., & Peer, D. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00607 · Cited by 88
Cooley, T. P., Henry, D. H., Tonda, M. E., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-114 · Cited by 85
Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D., Blackwelder, W. C., Gordon, E. M., & Hall, F. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.228 · Cited by 81
Nanomedicine and epigenome. Possible health risks
Smolková, B., Dušinská, M., & Gábelová, A. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.07.020 · Cited by 73
Hanigan, D., Truong, L., Schoepf, J., Nosaka, T., Mulchandani, A., Tanguay, R. L., & Westerhoff, P. (2018) · Water Research · doi:10.1016/j.watres.2018.03.062 · Cited by 69
Preclinical hazard evaluation strategy for nanomedicines
Siegrist, S., Çörek, E., Detampel, P., Sandström, J., Wick, P., & Huwyler, J. (2018) · Nanotoxicology · doi:10.1080/17435390.2018.1505000 · Cited by 69
Chen, K. T. J., Gilabert‐Oriol, R., Bally, M. B., & Leung, A. W. Y. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2654-z · Cited by 60
Considerations for the clinical use of contrast agents for cellular MRI in regenerative medicine
Modo, M., Kolosnjaj‐Tabi, J., Nicholls, F. J., Ling, W., Wilhelm, C., Debarge, O., Gazeau, F., & Clémеnt, O. (2013) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1547 · Cited by 53
Environmental Challenges for Nanomedicine
Baun, A., & Hansen, S. F. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.605 · Cited by 38
REGULATORY ROADMAP FOR NANOTECHNOLOGY BASED MEDICINES
Limaye, V., Fortwengel, G., & Limaye, D. (2018) · International Journal of Drug Regulatory Affairs · doi:10.22270/ijdra.v2i4.151 · Cited by 31
Assessing the Safety of Nanomedicines: A Mini Review
Dickinson, A. M., Godden, J. M., Lanovyk, K., & Ahmed, S. S. (2019) · Applied In Vitro Toxicology · doi:10.1089/aivt.2019.0009 · Cited by 27
Cited by
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 688
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Materials-Driven Soft Wearable Bioelectronics for Connected Healthcare
Gong, S., Lu, Y., Yin, J., Levin, A., & Cheng, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00502 · Cited by 411
A translational framework to DELIVER nanomedicines to the clinic
Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01754-7 · Cited by 333
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Metadata
- Authors
- Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C.
- Venue
- Biomaterials Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 8
- Issue
- 17
- Pages
- 4653-4664
- ISSN
- 2047-4830 (ISSN-L)
- 2047-4849
- OpenAlex
- W3042076644
- Cited by
- 568
- References
- 45
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.